Oxford Global’s free webinars: “drug discovery – what will the future hold?” registration open
Posted: 4 March 2016 | Oxford Global | No comments yet
This upcoming webinars hosted by Oxford Global will provide an insight on Drug Discovery & Antibody Research…
Webinar : March 15th | 2:30 pm GMT “Nanobodies as a Versatile and Clinically Validated Approach” hosted by Tony De Fougerolles, Chief Scientific Officer at Ablynx
This exciting webinar will discuss the exciting new antibody technology being developed by Ablynx, and aims to give attendees insight into the future of antibody discovery and development. Single domain antibodies represent a potential avenue for overcoming some of the limitations encountered by conventional antibody technology. As a leader in the field with over 40 active drug programmes, Ablynx has world-leading insight and experience in the use of immunoglobulin single variable domains, which we term Nanobodies®. Using both preclinical and clinical stage compounds as case studies, it will be shown how the use of Nanobodies can successfully address a range of concrete and distinct limitations of conventional antibody technology.
Register for free here
Webinar: March 22nd | 2:30 pm GMT “Open Innovation and partnerships for an improved Lead Generation” hosted by Patrick Jimonet, External Opportunities in Drug Discovery, Sanofi
This webinar will discuss a range of drug discovery strategies:
Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing
This report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.
Inside the report:
- Advance discovery through miniaturised, high-throughput and animal-free systems
- Integrate AI, robotics and analytics to speed decision-making
- Streamline cell therapy and bioprocess QC for scale and compliance
- And more!
This report unlocks perspectives that show how automation is changing the scale and quality of discovery. The result is faster insight, stronger data and better science – access your free copy today
- Diversity of modalities is required to drug challenging targets of pharma portfolios
- Hit Finding strategy: critical role of innovation and partnerships
- New business models to access novel chemical matter and technologies
- Macrocycles and cyclic peptides to drug proteins that failed with small molecules and/or that are not accessible to antibodies
- Open innovation, e.g. crowdsourcing, a new mindset to improve drug discovery efficiency
Register for free here
Benefits to Attending:
- Advance your knowledge of antibody technologies and the common challenges faced by researchers
- Hear about the latest strategies for open innovation in drug discovery, across small and large molecules
- Learn from a leading expert about his experience in antibody discovery
- Hear about an innovative approach to antibody technology and also open innovation, and have the opportunity to put your questions to our industry experts
You can also discover even more and discuss the latest topics in drug discovery and medicinal chemistry on our social media:
Twitter: https://twitter.com/drugdiscovery1
LinkedIn: Drug Discovery & Development Network Group
Related topics
Drug Discovery
Related organisations
Oxford Global
